China channel feed – Endpoints News

China channel feed

After attracting multiple Chinese pharma partners, XtalPi grabs another $400M to refine AI for drug discovery

4 years ago

As US review of Eli Lilly-partnered PD-1 gets underway, Innovent touts another frontline win in China

4 years ago

ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can't

4 years ago

Robert Bazemore inks one last deal for Epizyme — adding China to Tazverik's global blueprint — before heading out from CEO office

4 years ago

Chinese startup with Merck vet at the helm acquires rights to Oyster Point's eye disease nasal spray

4 years ago

Samantha Du's Zai Lab inks surprising research collab with Schrödinger for DNA damage drug

4 years ago

With clinical trials lined up for Zentalis drugs, China's Zentera sets its sights on more dealmaking and an IPO

4 years ago

BeiGene looks to carve out more space in the US market, setting up BTK drug for 2nd blood cancer nod

4 years ago

Shooting straight for Venclexta, a seasoned Chinese CEO has global dreams for his startup

4 years ago

Chinese researcher — and former 'fugitive' — returns home after DOJ moves to drop a spate of cases

4 years ago

As healthcare heats up on HKEX, Qiming sets up $500M fund dedicated to public companies

4 years ago

After chiming in antibody to Covid-19 fight, Junshi drops $30M to kick off mRNA joint venture in China

4 years ago

A Novartis castoff with a troubled past headlines Chinese biotech's Hong Kong IPO quest

4 years ago

Chinese antibody player chases Hong Kong IPO with lead Rituxan challenger ready for late-stage test

4 years ago

AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer

4 years ago

Discovery by Shanghai scientists inspires new plan of ATTEC for protein degradation

4 years ago

Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to carry on with pipeline for infectious diseases and beyond

4 years ago

With Eli Lilly's backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party

4 years ago

In search of a post-Tecfidera hit for MS, Biogen follows Sanofi, Roche down the BTK path — and bets $125M cash on a drug out of China

4 years ago

Chinese health authority erects new gold standard in oncology R&D, spooking investors in booming field

4 years ago

Sirnaomics puts off an IPO a little longer as it pockets another megaround. Is an S-1 around the corner this time?

4 years ago

Former Viela CEO Bing Yao finds his next gig — bringing Chinese R&D innovation stateside

4 years ago

Yescarta goes to China as Fosun Kite nabs historic first CAR-T OK

4 years ago

Allogene, Overland woo an experienced hand from WuXi to steer their allogeneic CAR-T JV

4 years ago

First page Previous page 12 13 141516 17 18 Next page Last page